精神分裂症门诊病人健康转归临床观察研究PPT课件.pptVIP

3年后体重增加的情况 0.0 与基线时体重相比(公斤) 再普乐 利培酮, 喹硫平, 氟哌啶醇 再普乐: 中位数: 4.5 kg 范围:-40 to 32 kg 利培酮, 喹硫平, 氟哌啶醇 : 中位数: 3.0 kg 范围:-29 to 35 kg 百分比 关键性的发现 在基线时换用/始用再普乐的患者相对于在基线时换用/始用利培酮、喹硫平、或氟哌定醇的患者更有可能 (p.001) 坚持它们基线时的单一药物治疗 (适用于所有明确或可能中断治疗的患者). 在基线时换用/始用利培酮的患者相对于在基线时换用/始用喹硫平、或氟哌定醇的患者更有可能 (p.001) 坚持它们基线时的单一药物治疗 (仅适用于明确中断治疗的患者) 在36个月的治疗之后许多早期CGI得分的改善有所削弱 关键性的发现 在第36个月，唯一的统计分离体现在阴性症状上，使用再普乐的患者相对于使用氟哌定醇的患者有明显改善。 换用/始用再普乐的患者相对于换用/始用喹硫平或氟哌定醇的患者更有可能 (p.001) 对他们在基线时的单一用药产生反应。 所有抗精神病药物在长时间用药过程中都与体重增加相关，但是平均体重增加总是在使用再普乐的患者身上更为明显 不管采用何种抗精神病药物治疗，体重增加的个体差异总是很大 结论 在世界范围内对于自然状态下门诊患者群普遍缺乏研究的背景下，洲际-SOHO对于抗精神病药物长期治疗与临床性的和功能性的结果的相关性提供了重要的认识 对这些数据的进一步探讨将帮助我们进一步阐明这些相关性. The IC-SOHO study was designed to evaluate a large and diverse population, over an extended period of time. There are parallel SOHO studies in Europe (EU-SOHO)1 and Brazil, results from both will ultimately provide the current study with a wider perspective, all contributing to the overall SOHO database that will contain a wealth of information. 1 Haro JM, Edgell ET, Jones PB, et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment. Acta Psychiatr Scand 2003;107:222-232 Abstract Objective: Non-interventional, naturalistic studies facilitate examination of current clinical practices, and afford us an understanding of the impact of the biopsychosocial aspects of schizophrenia. We present key findings from a pan-regional (n=27 countries) 3-year observational study. All treatment groups are non-randomised and there is no intervention to blind. Section 2 Page 6?of?14 IC-SOHO captures a large and diverse sample population with schizophrenia from 27 countries across 4 continents The size of the IC-SOHO study not only allows analysis of overall findings for the entire intercontinental sample, but also allows compa利培酮ons of findings within and between continents and countries. These countries are; Algeria, Argentina, Chile, Colombia, Costa Rica, Czech Republic, Egypt, El